We are people with MS trying to make a difference.  Evidence shows that a one 1 hour procedure can alleviate many MS symptoms, but it's a non-pharmaceutical solution, so the trial at The Alfred in Melbourne is not being funded. MS Australia have described this trial as vital we need your support to help this happen, The total cost of the ongoing vascular clinical trial  is $450,000 of which nearly $260,000 has already been achieved primarily as a result of purpose specific donations by the MS community and Service Organisations and Charities. Your help will make a real difference.


HoriZons This trial, under the guidance of Professor Ken Thomson and Dr Helen Kavnoudias involves 160 participants. While more than this number are on the waiting list further funding is needed - find out how you can help. In 2014 Helen described the trial in the following terms ''this project is highly significant as it will be the first blinded and randomised clinical trial conducted to determine whether there is any benefit in performing PTA in MS patients. The objectives of this study are to determine whether PTA treatment can restore blood flow through these vessels and whether this can relieve the negative effects suffered by MS patients.'' RM3005MS When referring to pre-trial outcomes Helen said ''42 people with MS and venous abnormalities were treated in a pre-trial at The Alfred in 2010. Patients reported improvements in vision, mobility, balance, fatigue, cognition and heat tolerance amongst other things. Such functional improvements were reported that people were returning to full time work and made decisions to start families. This was enough evidence to warrant further investigation. However, in the meantime access to this treatment has been halted until a randomised, double-blinded, controlled trial (RCT) is completed to show safety and efficacy. This research has the potential to improve the quality of life of 23,000 Australians. In March 2015 the International Society for Neurovascular Disease (ISNVD) in partnership with the Annette Funicello Research Fund for Neurological Disease (AFRFND) selected the Alfred CCSVI clinical trial trial as one of four recipients of its 2015 research grants.  In announcing these grants Society President, Professor Ziv J Haskal M.D. said "With these grants, the AFRFND takes a substantial step forward in directly supporting sophisticated research into palliating, treating and curing neurovascular diseases, such as MS.  Our grant winners represent a remarkably broad range of study, from controlled trials to basic receptor science. I expect great things, It is great that the ISNVD are now stakeholders in this very important CCSVI research. It is equally heartening that Australian researchers are recognised by their peers as being on the world stage with their contribution to neurovascular research with respect to multiple sclerosis. All in all, a great patient-centred effort - congratulations to Helen, Ken and the fantastic team of quiet achievers who are making this happen.